Cholangiocarcinoma

Buckholz, Adam; Brown, Robert S.

doi:10.1016/j.cld.2020.04.005

Cited by 26 publications

(5 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Premalignant lesion such as HGD of the cystic duct is a precursor of cystic duct carcinoma; however, due to its rarity, it is often grouped together with cholangiocarcinoma (CCA), gallbladder cancer or cancers of the biliary tree 6. HGD is a late-stage component of the epithelial cancer progression from normal cells to hyperplasia or metaplasia, dysplasia (low and high grade) and eventually carcinoma 7 8.…”

Section: Discussionmentioning

confidence: 99%

High-grade dysplasia of the cystic duct margin: how should this be managed?

Andersen,

Goh,

Siriwardhane

2023

BMJ Case Rep

View full text Add to dashboard Cite

High-grade dysplasia (HGD) in the cystic duct is a rare epithelial lesion that may lead to biliary tract malignancy. Due to its association with aggressive multifocal cholangiocarcinoma, it is important to investigate for concurrent malignancy, remove all areas of HGD and monitor for recurrence or metastasis.We present a case of a woman in her 60s with cholecystitis who underwent a laparoscopic cholecystectomy. On histopathology, the patient was found to have incidental HGD involving the cystic duct margin. After ensuring the absence of concurrent malignancy on cross-sectional imaging, she underwent further resection until the margins were clear of dysplasia. In the absence of clear follow-up guidelines, the patient was closely monitored with outpatient scans for up to 5 years.

show abstract

Section: Discussionmentioning

confidence: 99%

High-grade dysplasia of the cystic duct margin: how should this be managed?

Andersen,

Goh,

Siriwardhane

2023

BMJ Case Rep

View full text Add to dashboard Cite

show abstract

“…Cholangiocarcinoma is currently one of the most common causes of death in PSC patients who do not undergo transplantation. 37,38 The usual manifestations are epigastric pain, liver biochemical deterioration, jaundice, and elevated serum CA19.9. Chemotherapy remains the primary palliative treatment for patients with cholangiocarcinoma.…”

Section: Management Of Complications Of Pscmentioning

confidence: 99%

Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going?

Luo,

2024

J Clin Transl Hepatol

View full text Add to dashboard Cite

Cholestatic liver disease is a group of diseases in which bile acid accumulates in the liver for various reasons, resulting in abnormal liver biochemical indicators and histological damage. Cholestasis can be divided into intrahepatic cholestasis and extrahepatic cholestasis, which will contribute to liver damage and progress to liver fibrosis and cirrhosis. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis are the two most typical cholestatic liver diseases. Ursodeoxycholic acid is currently the first-line treatment for PBC, while obeticholic acid, budesonide and fibrates have also shown good potential in the treatment of PBC. There are currently no official drugs approved to treat primary sclerosing cholangitis, and the use of ursodeoxycholic acid may have certain clinical benefits. At present,

show abstract

“…Overall, the 5-year survival rate remains low after resection for CCA in clinical settings, reported in the range of 40-60% for intrahepatic CCA, 30-50% for perihilar CCA and 27-37% for distal CCA. 15 Therefore, it is essential to seek potential diagnostic biomarker, therapeutic targets, and understand the molecular mechanisms underlying the progression of CCA.…”

Section: A Hepatocellular Carcinoma (Hcc) Cholangiocarcinoma (Cca) An...mentioning

confidence: 99%

Circadian Rhythm and Melatonin in Liver Carcinogenesis: Updates on Current Findings

et al. 2021

View full text Add to dashboard Cite

Liver cancer, including hepatocellular carcinoma and cholangiocarcinoma, can be devastating if not treated early. The risk factors of liver cancer include alcoholic liver disease, non-alcoholic fatty liver disease, disruption of melatonin levels, and dysregulated circadian rhythm. The circadian rhythm is a 24-hour biological clock that regulates the physiological activities at both central and peripheral levels. Its molecular mechanism exists in every cell in mammals. Disruption of the circadian rhythm has found in liver cancers as an independent risk factor. This review summarized the most recent findings about the molecular mechanisms of circadian rhythm, the crosstalk between core clock genes and melatonin, as well as the role of circadian rhythm and melatonin played in chronic liver diseases and liver cancer. Finally, we discussed the potential clinical application of circadian rhythm and melatonin for the treatment of liver cancer and discussed future perspectives of how understanding the circadian rhythm in liver cancer progression could provide new clinical applications for liver cancer treatment and diagnosis.

show abstract

Cholangiocarcinoma

Cited by 26 publications

References 91 publications

High-grade dysplasia of the cystic duct margin: how should this be managed?

High-grade dysplasia of the cystic duct margin: how should this be managed?

Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going?

Circadian Rhythm and Melatonin in Liver Carcinogenesis: Updates on Current Findings

Contact Info

Product

Resources

About